BioNTech (BNTX) Expected to Announce Quarterly Earnings on Tuesday

BioNTech (NASDAQ:BNTX) is expected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect BioNTech to announce earnings of ($2.3999) per share and revenue of $183.7470 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, May 4th. The company reported ($2.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.52) by $0.26. The company had revenue of $136.71 million during the quarter, compared to analyst estimates of $207.42 million. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. BioNTech’s quarterly revenue was down 35.4% compared to the same quarter last year. During the same period last year, the business earned ($1.73) EPS. On average, analysts expect BioNTech to post $-6 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

BioNTech Stock Up 2.0%

Shares of BioNTech stock opened at $91.09 on Tuesday. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00. The firm has a market cap of $23.04 billion, a price-to-earnings ratio of -15.49 and a beta of 1.32. The company has a 50-day moving average of $91.33 and a 200 day moving average of $97.63. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.80 and a quick ratio of 8.74.

BioNTech announced that its board has approved a stock repurchase program on Thursday, May 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 4.2% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of the company. EFG International AG bought a new position in shares of BioNTech in the fourth quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd increased its position in shares of BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after acquiring an additional 260 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of BioNTech by 118.2% during the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after acquiring an additional 305 shares in the last quarter. NewEdge Advisors LLC purchased a new position in BioNTech in the 1st quarter worth approximately $167,000. Finally, Osaic Holdings Inc. raised its holdings in BioNTech by 27.3% in the 2nd quarter. Osaic Holdings Inc. now owns 1,949 shares of the company’s stock worth $208,000 after acquiring an additional 418 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BNTX shares. Wall Street Zen upgraded shares of BioNTech from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. UBS Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the company from $117.00 to $135.00 in a report on Wednesday, May 27th. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Canaccord Genuity Group cut their price target on BioNTech from $171.00 to $158.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $129.12.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.